Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice

International Journal of Antimicrobial Agents

Volumn 30, Issue 4, 2007, Pages 336-340

  Dutta, Noton Kumar ^a,b   Mazumdar, Kaushiki ^a,b   Dastidar, Sujata G ^b   Park, Jae Hak ^a  

^a Seoul National University   (South Korea)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Antimycobacterial agents; Diclofenac; In vivo; Streptomycin; Synergism; Tuberculosis

Indexed keywords

DICLOFENAC; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIUM ISOLATE; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; LUNG; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN WEIGHT; SURVIVAL RATE; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; LUNG; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; STREPTOMYCIN; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 34548480263     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.04.016     Document Type: Article

References (15)

1. Dutta N.K., Mazumdar K., Dastidar S.G., Chakrabarty A.N., Shirataki Y., and Motohashi N. In vitro and in vivo antimycobacterial activity of an antihypertensive agent methyl-l-DOPA. In Vivo 19 (2005) 539-545
2. Dastidar S.G., Basu S., Annadurai S., et al. In vitro and in vivo antibacterial activity of the antiinflammatory agent diclofenac sodium. Recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy (ICC); 27 June-2 July 1993; Stockholm, Sweden (1994), ASM Press, Washington DC 339-340
3. Mazumdar K., Dutta N.K., Dastidar S.G., Motohashi N., and Shirataki Y. Diclofenac in the management of E. coli urinary tract infections. In Vivo 20 (2006) 613-619
4. Dutta N.K., Kumar K.A., Mazumdar K., and Dastidar S.J. In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium. Indian J Exp Biol 42 (2004) 922-927
5. Dutta N.K., Dastidar S.G., Kumar A., et al. Antimycobacterial activity of the antiinflammatory agent diclofenac sodium, and its synergism with streptomycin. Braz J Microbiol 35 (2004) 316-323
6. Annadurai S., Guha-Thakurta A., Sa B., Dastidar S.G., Ray R., and Chakrabarty A.N. Experimental studies on synergism between aminoglycosides and the antimicrobial antiinflammatory agent diclofenac sodium. J Chemother 14 (2002) 47-53
7. Dastidar S.G., Annadurai A., Kumar K.A., Dutta N.K., and Chakrabarty A.N. Evaluation of a synergistic combination between the non-antibiotic microbicides diclofenac and trifluoperazine. Int J Antimicrob Agents 21 (2003) 599-601
8. De Logu A., Onnis V., Saddi B., Congiu C., Schivo M.L., and Cocco M.T. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 49 (2002) 275-282
9. Truffot-Pernot C., Ji B., and Grosset J. Activities of perfloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 72 (1991) 57-64
10. Dastidar S.G., Ganguly K., Chaudhuri K., and Chakrabarty A.N. The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int J Antimicrob Agents 14 (2000) 249-251
11. Sriram D., Yogeeswari P., and Devakaram R.V. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. Bioorg Med Chem 14 (2006) 3113-3118
12. Ordway D., Viveiros M., Leandro C., et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 917-922
13. Byrne S.T., Denkin S.M., and Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother 59 (2007) 313-316
14. Sano C., Shimizu T., Sato K., Kawauchi H., Kawahara S., and Tomioka H. Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 43 (1999) 360-364
15. Amaral L., Viveiros M., and Kristiansen J.E. 'Non-antibiotics': alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 7 (2006) 887-891